Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
BioNexus Gene Lab's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $1.41.
The industry rank for BioNexus Gene Lab's Net-Net Working Capital or its related term are showing as below:
BGLC's Price-to-Net-Net-Working-Capital is ranked better than 96.77% of 588
companies
in the Chemicals industry
Industry Median: 7.925
vs BGLC: 1.13
BioNexus Gene Lab (NAS:BGLC) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
BioNexus Gene Lab Net-Net Working Capital Related Terms
BioNexus Gene Lab Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs VYST, QGAI, CNEY: Net-Net Working Capital Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Price-to-Net-Net-Working-Capital vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $1.41 mean?
BioNexus Gene Lab (BGLC) has a Net-Net Working Capital of $1.41 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on BioNexus Gene Lab According to the industry distribution chart, BioNexus Gene Lab ranks #19 out of 588 companies in the Chemicals industry, placing it in the top 3.2%.
Is BioNexus Gene Lab's Net-Net Working Capital too high?
BioNexus Gene Lab's current Net-Net Working Capital is $1.41. The Chemicals industry median Net-Net Working Capital is 7.93. BioNexus Gene Lab's value of $1.41 is 82.2% below this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #19 out of 588 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Net-Net Working Capital compare to VYST and QGAI?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #19 out of 588 companies for Net-Net Working Capital. This places BioNexus Gene Lab in the top 3% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 7.93. BioNexus Gene Lab's value of $1.41 is 82.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Chemicals company?
The median Net-Net Working Capital among Chemicals companies is 7.93, based on 588 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Net-Net Working Capital of $1.41 is 82.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on BioNexus Gene Lab For the Chemicals industry, the median Net-Net Working Capital is 7.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Net-Net Working Capital is $1.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.14, compared to a current price of $1.60 — trading 25.2% below its estimated fair value. The current Net-Net Working Capital is $1.41 and 82.2% below the Chemicals industry median of 7.93. BioNexus Gene Lab's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Net-Net Working Capital is $1.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.60 is trading 25.2% below its estimated GF Value™ of $2.14.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Net-Net Working Capital: $1.41
GF Value™: $2.14 vs. price of $1.60 (25.2% below fair value)
Industry Position: 82.2% below the Chemicals median (#19 of 588)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
54GF Score
Get the complete analysis for BGLC
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
